Global Chronic Obstructive Pulmonary Disease Treatment – GlobeNewswire

Global Market Report: Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices

Executive Summary

The global market for Chronic Obstructive Pulmonary Disease (COPD) treatment devices is projected to experience robust growth, with a Compound Annual Growth Rate (CAGR) of approximately 6% between 2025 and 2032. This expansion is critical for advancing SDG 3 (Good Health and Well-being) by improving the management of non-communicable diseases. Key market drivers include the rising global incidence of COPD, demographic shifts towards aging populations, and persistent environmental risk factors such as poor air quality, which directly relates to SDG 11 (Sustainable Cities and Communities). Furthermore, technological innovation in medical devices is a significant catalyst, supporting SDG 9 (Industry, Innovation, and Infrastructure). North America is expected to maintain its dominant market position throughout the forecast period.

Market Dynamics and Alignment with Sustainable Development Goals

The dynamics of the COPD treatment devices market are intrinsically linked to several Sustainable Development Goals. The market’s growth is propelled by factors that address global health challenges, while its barriers highlight areas requiring concerted effort to ensure equitable access.

Market Drivers

• Global Burden of COPD: The increasing prevalence of COPD as a leading cause of morbidity and mortality presents a direct challenge to SDG 3.4, which aims to reduce premature deaths from non-communicable diseases. The growing demand for treatment devices is a direct response to this global health imperative.
• Prevalence of Risk Factors: Widespread risk factors, including tobacco use, air pollution, and occupational exposure to harmful substances, underscore the need for effective respiratory therapies. Addressing occupational health aligns with SDG 8 (Decent Work and Economic Growth), while tackling air pollution is central to SDG 11.
• Increased Awareness and Screening: Enhanced public awareness campaigns and expanded screening programs lead to earlier diagnosis and intervention, increasing the adoption of devices and contributing positively to health outcomes as envisioned in SDG 3.

Market Barriers

• High Cost and Accessibility: The significant cost of advanced respiratory devices poses a major barrier, particularly in low- and middle-income countries. This challenge directly impedes progress towards SDG 10 (Reduced Inequalities) by creating disparities in healthcare access.
• Inconsistent Reimbursement Policies: A lack of uniform reimbursement policies across different regions can limit patient access to necessary treatments, further exacerbating the health inequalities targeted by SDG 10.
• Lack of Awareness in Developing Regions: Insufficient awareness in certain regions hinders early diagnosis and treatment, working against the public health objectives of SDG 3.

Technological Innovation and Contribution to SDG 9

Technological advancement is a cornerstone of market growth and a key contributor to SDG 9 (Industry, Innovation, and Infrastructure). The industry is shifting towards developing more effective, patient-centric solutions.

1. Smart and Portable Devices: The development of smart inhalers, which monitor usage and improve patient adherence, and portable oxygen concentrators, which enhance patient mobility and quality of life, exemplifies innovation in action. These advancements directly support the targets of SDG 3 by improving treatment efficacy and patient well-being.
2. Home-Based Care Solutions: Innovations are increasingly focused on supporting home-based care. This trend not only reduces healthcare costs but also builds more resilient and decentralized healthcare systems, a key aspect of ensuring good health for all (SDG 3).
3. User-Friendly Designs: Recent product approvals, such as OHTUVAYRE (ensifentrine) delivered via a standard jet nebulizer, eliminate the need for complex coordination, making treatment more accessible for elderly patients or those with severe symptoms. This focus on inclusive design promotes health equity.

Regional Market Analysis

In 2024, North America held the dominant share of the global COPD treatment devices market. This leadership is attributed to several factors:

• A high prevalence of COPD linked to lifestyle and environmental factors.
• A robust healthcare infrastructure and the strong presence of key industry players, which fosters innovation and contributes to regional economic growth (SDG 8).
• A favorable regulatory environment, evidenced by recent FDA approvals, which accelerates the availability of new treatments and supports the goals of SDG 3 and SDG 9.

Market Segmentation

• By Product Type:
  • Inhalers (Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, and Others)
  • Nebulizers (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer)
• By End-User:
  • Hospitals & Clinics
  • Homecare Settings
  • Others
• By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Key Stakeholders and Partnerships for the Goals (SDG 17)

The market is characterized by the active participation of numerous MedTech and pharmaceutical companies. The collaborative efforts between these entities, regulatory bodies, and healthcare systems are essential for driving progress and exemplify SDG 17 (Partnerships for the Goals).

Notable Market Participants

• Koninklijke Philips N.V.
• Omron Healthcare, Inc.
• Aerogen
• Medtronic
• Novartis AG
• AstraZeneca
• Lupin
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Verona Pharma plc.

These stakeholders contribute to achieving global health targets through continuous research, product development, and strategic initiatives aimed at expanding market access. Recent activities, such as Lupin’s launch of a generic Tiotropium Bromide Inhalation Powder and Verona Pharma’s FDA approval for OHTUVAYRE, highlight the dynamic nature of the market and its ongoing contribution to improving global respiratory health in line with the Sustainable Development Goals.

Analysis of SDGs, Targets, and Indicators in the Article

1. Which SDGs are addressed or connected to the issues highlighted in the article?

• SDG 3: Good Health and Well-being

  The article’s central theme is Chronic Obstructive Pulmonary Disease (COPD), a major non-communicable disease. It discusses the disease’s prevalence, causes, and treatment, directly aligning with the goal of ensuring healthy lives. The text states that COPD is one of the “leading causes of morbidity and mortality worldwide” and that treatment devices “play a critical role in managing symptoms, improving lung function, and enhancing the quality of life for patients.”

• SDG 9: Industry, Innovation, and Infrastructure

  The article extensively covers the role of innovation in the COPD treatment market. It highlights how “leading companies are also focusing on innovation, launching portable, smart, and user-friendly devices” and how “technological advancements are also playing a significant role in shaping market dynamics.” This focus on research, development, and technological upgrades in the medical device industry connects directly to SDG 9.

• SDG 11: Sustainable Cities and Communities

  The article identifies environmental factors prevalent in urban and industrial areas as key drivers of COPD. It mentions “worsening air quality,” “indoor and outdoor air pollution,” and “industrial pollutants” as significant risk factors. This links the health issue to the environmental quality of human settlements, a core concern of SDG 11.

• SDG 12: Responsible Consumption and Production

  This goal is relevant through the mention of pollution sources that contribute to COPD. The article points to “occupational exposure to harmful dust and chemicals” and “industrial pollutants” as causes. This implies a connection to industrial production patterns and the need for environmentally sound management of chemicals and wastes to protect human health.

2. What specific targets under those SDGs can be identified based on the article’s content?

1. SDG 3: Good Health and Well-being

   • Target 3.4: By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment. The article focuses on managing COPD, a chronic non-communicable respiratory disease, through treatment devices to “improve survival rates” and enhance quality of life.
   • Target 3.8: Achieve universal health coverage, including access to quality essential health-care services and affordable essential medicines. The article discusses the “adoption of devices like inhalers, nebulizers, and oxygen concentrators” but also notes barriers like the “high cost of advanced respiratory care devices” and “lack of awareness in low- and middle-income countries,” which are central challenges to achieving this target.
   • Target 3.9: By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contamination. The article directly links the “rising incidence of chronic obstructive pulmonary disease” to risk factors like “worsening air quality,” “air pollution,” and “occupational exposure to harmful dust and chemicals.”

2. SDG 9: Industry, Innovation, and Infrastructure

   • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, including encouraging innovation. The article is replete with examples, such as the development of “smart inhalers and portable oxygen concentrators,” the “integration of digital health technologies,” and new product approvals like “OHTUVAYRE (ensifentrine),” which all represent innovation in the medical technology sector.

3. SDG 11: Sustainable Cities and Communities

   • Target 11.6: By 2030, reduce the adverse per capita environmental impact of cities, including by paying special attention to air quality. The article explicitly states that “worsening air quality” and “outdoor air pollution” are amplifying the demand for COPD treatment devices, highlighting the direct impact of urban air quality on public health.

4. SDG 12: Responsible Consumption and Production

   • Target 12.4: By 2020, achieve the environmentally sound management of chemicals and all wastes… and significantly reduce their release to air… to minimize their adverse impacts on human health. The mention of “industrial pollutants” and “occupational exposure to harmful dust and chemicals” as risk factors for COPD points to the health consequences of production processes that do not manage chemical releases responsibly.

3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?

1. For SDG 3 (Good Health and Well-being)

   • Indicator for Target 3.4: The article refers to COPD as one of the “leading causes of morbidity and mortality worldwide.” Therefore, the mortality rate from chronic respiratory disease (Indicator 3.4.1) is a directly relevant metric.
   • Indicator for Target 3.8: The “adoption of devices,” “market penetration,” and “patient adherence” are implied indicators of access to essential healthcare. Conversely, the “high cost of advanced respiratory care devices” and “inconsistent reimbursement policies” are mentioned as barriers, which can be measured to track progress towards financial risk protection.
   • Indicator for Target 3.9: The “rising incidence of chronic obstructive pulmonary disease” linked to pollution serves as an implied indicator for the health impact of air pollution (related to Indicator 3.9.1, mortality rate attributed to household and ambient air pollution).

2. For SDG 9 (Industry, Innovation, and Infrastructure)

   • Indicator for Target 9.5: The article provides several examples that can serve as qualitative indicators of innovation, such as the “launching portable, smart, and user-friendly devices,” the “integration of digital health technologies,” and the number of “product approvals” by regulatory bodies like the FDA. The projected market growth (“CAGR of ~6%”) also reflects the impact of this innovation.

3. For SDG 11 (Sustainable Cities and Communities)

   • Indicator for Target 11.6: While not providing data, the article identifies “worsening air quality” as a key problem. The prevalence and incidence rates of COPD that are specifically attributed to urban air pollution can serve as an indirect health-based indicator for air quality (related to Indicator 11.6.2, annual mean levels of fine particulate matter).

4. For SDG 12 (Responsible Consumption and Production)

   • Indicator for Target 12.4: The article mentions “occupational exposure to harmful dust and chemicals” as a risk factor. The incidence of COPD within specific industrial sectors or occupations can be used as an implied indicator to measure the adverse health impacts from chemical and pollutant releases.

4. Table of SDGs, Targets, and Indicators

Source: globenewswire.com